Introduction
Since 2000, the surveillance of childhood cancer in France has been national: the French National Registry of Childhood Haematopoietic Malignancies (NRCH) has recorded all cases of haematological malignancies including lymphoma since 1990 and the French National Registry of Childhood Solid Tumours (NRCST) has recorded all cases of solid tumours except lymphomas since 2000. The two registries cover the entire population of mainland France aged less than 15 years (about 11 million children). Earlier, for the period 1990-1999, French childhood cancer incidence data on blood malignancies were reported by the NRCH and data on all tumours by the local registries, which, at that time, covered 32% of mainland France (Desandes et al., 2004) . This study, which analyses the childhood cancer cases registered by the NRCH and NRCST over the period [2000] [2001] [2002] [2003] [2004] , is the first report on the incidence of all childhood cancers in France on a nationwide basis.
Materials and methods

Population covered
Population data were provided by the French Institute of Statistics and Economic Studies for each year until 2006. The number of births slightly increased till 2002 and the child population was rather stable over that period, varying overall from 11 084 873 children aged less than 15 years in 2000 to 11 156 015 children in 2004 (Table 1) . For a given year , person-years were computed by years of age and sex as the mean of the populations in each year and the next one.
Case registration
All incident cases of malignancies in children (age: 0-14 years) resident in mainland France at the time of diagnosis are included in the French national registries. The NRCH specifically records haematological malignancies while the NRCST records malignant solid tumours. In line with the recommendations of the European Network of Cancer Registries (Tyczynski et al., 2003) and the International Classification of Childhood Cancer (ICCC) (Steliarova-Foucher et al., 2005) , benign tumours of the central nervous system (CNS) are also recorded. Data are actively collected by trained investigators in all paediatric haematology and oncology departments and paediatric neurosurgery departments (about 40 centres). Active registration is supplemented by an annual request for claim data from the Information System Medicalization Programme (ISMP) of the University Hospitals and Comprehensive Cancer Centres, which lists all children aged less than 15 years who have been admitted to any department with a diagnosis of cancer, brain tumour or a few borderline diagnoses. This source of information enables identification of children with cancer treated in other departments such as orthopaedic, visceral, and ear nose and throat surgery and endocrinology departments, as some tumours, such as thyroid, brain and germinal tumours, are not always treated by a paediatric oncologist. Data collection is also based on therapeutic networks, but the number of cases enrolled in clinical trials depends on tumour type and period, as there may be gaps of several years in clinical trial registration. Finally, cases of cancer that are fatal before transfer to a specialized department (mainly neonatal cases) are retrieved from the INSERM Department responsible for information on the medical causes of deaths (Cepi-Dc), using a twostep process to obtain the children's names in compliance with statutory requirements. Only cases born after the corresponding registry had started (1990 for NRCH and 2000 for NRCST) were sought in the death files. Thus no case was registered on the basis of a death certificate only.
Data collection
The registration form, which is common to both registries, includes identification data (first and last names, sex, date and place of birth, address at diagnosis), diagnostic data (incidence date, basis of diagnosis, method of first detection, site of primary tumour, histological type, immunophenotype and genetics, stage at diagnosis, laterality, histological grade), patient pathway from diagnosis to treatment, initial treatment (date of treatment initiation, cancer treatment type), vital status and last contact date. The diagnoses are coded using the International Classification of Disease -Oncology, third edition (ICD-O-3) (Fritz et al., 2000) and grouped further using the ICCC-third revision (Steliarova-Foucher et al., 2005) .
Each of the two registries has its own database, developed using 4D software and including procedures to detect duplicates and check compliance with the exclusion rules (age 15 years or more, residing outside mainland France at diagnosis). The registries have been approved by the national information technology monitor (CNIL) responsible for the protection of nominal data and accredited by the French National Committee of Registries.
Data analysis
All the cases included in the NRCH or NRCST and occurring between 1 January 2000 and 31 December 2004 were retrieved, tabulated by tumour type and categorized using the ICCC-3 levels: 12 main diagnostic groups, 47 diagnostic subgroups, and 2-11 divisions of selected subgroups (Steliarova-Foucher et al., 2005) . The incidence rates (IRs) were calculated for the 5-year period, 2000-2004, and based on person-years derived from the Institute of Statistics and Economic Studies annual estimates of population by age and sex. Crude and age-specific IRs were calculated and age-standardized rates (ASRs) were estimated by the direct method using the world population for the age groups under 15 years (Parkin et al., 1998) . Cumulative rates, defined as the sum of the agespecific IRs over each year of age from 0 to 14 years, were also calculated (Parkin et al., 1998) . The male/female ratio was the ratio of the number of cases in boys to that in girls. To compare the present data with data published earlier (Desandes et al., 2004) , the IRs for the regions that had been covered by the local registries in the past were calculated.
Results
A total of 8473 cases were registered during the period 2000-2004, which consisted of 3446 cases of haematological malignancies and 5027 cases of solid tumours.
Sources of information and quality criteria
As expected, the cases were mainly registered from hospital departments' medical records, especially paediatric oncology and neurosurgery departments ( Table 2) . About 87% of the cases were retrieved from ISMP files and the distribution by diagnostic group did not differ greatly. In contrast, the proportion of cases reported for clinical trials, one third of the cases overall, differed markedly depending on the diagnostic group (from 0% for melanoma and other epithelial tumours to 70% for hepatic tumours).
Death files constituted a minor source of data, contributing to identification of about 8% of the cases.
Overall, the average number of sources was 2.7. The diagnosis was documented by cytology/histology in 94% of cases, ranging from 62% for retinoblastoma to 100% for bone tumours. There were no missing data on date of birth, sex or place of residence. 
Description of cases and incidence rates
Over the period from 2000 to 2004, the ASR for all cancers was 156.6 cases per million children per year ( Table 3) . The most frequent cancers were leukaemia (29%) and CNS tumour (23%). Lymphoma accounted for 12%, neuroblastoma 8%, and soft-tissue sarcoma and renal tumour for about 6% of the cases. Other tumours were rare. The number of cases was slightly higher for boys (overall sex ratio: 1.2), especially for mature B-cell leukaemia (sex ratio: 3.8), lymphoma (particularly Burkitt lymphoma), medulloblastoma, hepatic tumour, Ewing tumour, soft-tissue sarcoma and intracranial germ cell tumour. Conversely, extracranial germ cell tumour and carcinoma and thyroid carcinoma were more frequent in girls.
As shown in Table 4 , 45% of all cases were observed in children less than 5 years old while the other cases were equally distributed across the two upper age groups (5-9 and 10-14 years). The expected marked differences in the age patterns of the specific categories of cancer were observed: embryonal tumours such as Wilms tumour, hepatoblastoma, retinoblastoma and neuroblastoma were mainly diagnosed before the age of 5 years and, for about one third of those tumours, before the age of 1 year. Acute lymphoid leukaemia (ALL) peaked in the age group 1-4 years. After the age of 10 years, other cancers became more frequent, particularly lymphoma, bone tumour and even epithelial neoplasm. The specific patterns of the various types of cancers are shown in Fig. 1 , which shows the variations in incidence with age. Before the age of 1 year, the most common malignancies were neuroblastoma (31%), CNS tumour (15%), leukaemia (14%), among which acute nonlymphocytic leukaemia was as frequent as ALL, retinoblastoma (12%) and Wilms tumour (8%).
From 1 to 5 years, the most frequent neoplasms remained (in different proportions): leukaemia (37%), especially ALL, CNS tumour (22%), neuroblastoma (11%) and Wilms tumour (10%). In the 5-9 years age group, ALL accounted for 32% of all cases, CNS tumour for 23% and lymphoma for 14%. These groups of cancer, and bone tumours (10.7%), remained the most frequently diagnosed in children aged above 10 years.
Overall, the ASR over 2000-2004 was 158.4 per million children per year for the population covered by the French local registries during the 1990s (Table 5 ). The IRs were close to those observed on the national scale for all the diagnostic groups.
Discussion
This study describes the incidence of childhood cancers in France, based, for the first time, on national data. The two national registries work closely together and comply with the international recommendations for data collection, registration and coding formulated by the International Agency for Research on Cancer (Tyczynski et al., 2003) . The strength of the study resides in the reliability of the data. Each case was systematically ascertained in the medical records by the investigators and documented by immunohistocytology reports. With the contribution of the clinical trials and an increasing number of hospital ISMP files, the average number of sources per case was high (2.7). Some tumours were not initially retrieved by actively searching the specific paediatric oncology or neurosurgery units but were obtained from ISMP files and then investigated in other hospital departments, such as dermatology departments for melanoma, and head and neck surgery and endocrinology departments for thyroid cancer. Thus, while 89% of the solid tumours were treated in paediatric oncology departments, only 72% of the CNS tumours and 61% of the melanomas and epithelial tumours were retrieved from those departments.
Thyroid tumours are also treated in adult units in hospitals not routinely investigated by the registries. A particular request forwarded to about 20 nuclear medicine units enabled registration of more than 96% of those tumours (Lacour and Francim, 2006) . In consequence, a specific request is to be issued to the nuclear medicine units every 3 years. Melanomas and other skin tumours may still be beyond registration as they may be treated in nonacademic healthcare institutions.
Over the period from 1990 to 1997, the exhaustiveness of the NRCH, tested by the capture-recapture method using the local registries as the other independent source, was estimated at 99.2% for leukaemia and 97.2% for lymphoma . Evaluation was not feasible for the period 2000-2004, because the national registries have been in charge of local registration since 2000 and there are no longer any local registries. However, the quality of the data should be at least as good as it was for the 1990-1997 period. The quality should even have improved since ISMP became available in 1997, with a growing number of hospital files available to the registries and an improvement in their quality since that time. In addition, the investigators became increasingly experienced in information retrieval. The IRs from the NRCH and the NRCST were substantially higher than those estimated by the French local registries over the period 1990-1999 (Table 5 ). The previous NRCH paper was already based on the ICD-O-3 classification but the publication based on local registries used the second version of ICD-O, which aggregated juvenile myelomonocytic leukaemia with chronic myeloid leukaemia, and considered myelodysplastic syndromes as borderline diseases when they had not undergone transformation into leukaemia or were not secondary to chemotherapy or radiotherapy.
Over the period from 2000 to 2004, the IRs in the regions that had been covered by the local registries were similar to the rates estimated for mainland France, and higher than the rates estimated for the period 1990-1999. This is likely to be due to the improved methodology with ISMP files, although an increase in some rates could not be ruled out. Notably, the annual standardized IR of CNS tumours (36.2 cases/million) was far higher than the IR estimated from local paediatric registries for 1990-1999 (29.1 cases/million). This difference was consistent with Age-specific incidence rates per million children of various types of childhood cancer (France, 2000 (France, -2004 . CNS, central nervous system; PNET, primitive neuroectodermal tumour.
other reports of an increase in incidence over time , especially for CNS tumours (Peris-Bonet et al., 2006) . Indeed, the annual IR estimated from the NRCST was close to the figures reported by the Surveillance, Epidemiology, and End Results (SEER) programme (37.3 cases/million) (Ries et al., 2008) for the same period, whereas the annual IRs in the USA (Li et al., 2008) , Germany and Switzerland (Michel et al., 2008) were lower (31.9, 32 and 30.4 cases/million, respectively). Discrepancies between the data from the SEER programme and the National Program of Cancer Registries may be owing to the lack of representativeness of the SEER programme, which only covered 10% of the US population. The National Program of Cancer Registries now provides data on 90% of the US population. There is no doubt that CNS tumour diagnosis has improved over the last 30 years, with the spread of computed tomography scanning and magnetic resonance imaging. The effects on CNS tumour IRs are clearly shown by the jump observed between 1984 and 1986 (Smith et al., 1998) . Since 1992, the incidence of CNS tumours seems to have stabilized in the USA, but there has nevertheless been a significant increase in gliomas among Hispanic children, possibly due to delayed access to improved diagnostic methods in lower socioeconomic strata (Linabery and Ross, 2008) . Such a delay could partly explain the higher incidence of CNS tumours observed in France over the period 2000-2004, compared with the incidence in 1990-1999. A more likely explanation is that registries have increased their exhaustiveness, particularly for tumours treated by surgery only, with the increase in computerized hospital files and ISMP at the end of the 1990s, and with the accreditation policies implemented in parallel, which restricted the number of departments qualified for paediatric care. This may particularly apply to benign brain tumours, which are primarily treated in neurosurgery departments. As stated above, this is clearly true for thyroid cancer, which was the target of active research in nuclear medicine departments, with IRs increasing from 1.1 to 1.9 cases per million per year between the two periods.
The present estimates of neuroblastoma IRs are higher than those in the USA (Li et al., 2008) and Germany for the same period. The difference was especially marked with respect to infants in the USA (USA: 57.8 vs. France: 75.1 cases/million/year), while, for Germany, the infantile annual IR was similar (79 cases/million/year), although lower after 1 year . The screening programmes and, more generally, improved access to medical care may explain these differences , as has also been suggested by the Childhood Cancer Registry of Piedmont, which observed a significant increase in the incidence of neuroblastoma in the first year of life during the 35-year period from 1967 to 2001, when no active screening was conducted in Piedmont. The registry reported an annual age standardized IR of 15.9 cases per million for neuroblastoma for the period 1997-2001 (Dalmasso et al., 2005) , which is consistent with the data reported herein. Retinoblastoma 5.0 (4.1-6.2) 5.2 (3.5-7.6) 3.7 (2.6-5.2) 4.0 4.6 Renal tumours 9.7 (8.3-11.3) 8.4 (6.1-11.5) 9.1 (7.3-11.4) 8.5 9 8.8 Hepatic tumours 1.4 (0.9-2.1) 1.8 (0.8-3.5) 1.5 (0.8-2.6) 2.2 2 2.4 Malignant bone tumours 6.7 (5.6-8.0) 7.0 (5.3-9.5) 6.6 (5.3-8.5) 6.7 6 6.5 Soft tissue and other extraosseous sarcomas 9.6 (8.1-11.4) 9.2 (6.6-12.6) 7.4 (5.7-9.6) 10.6 10 9.0
Germ cell tumours, trophoblastic tumours and neoplasms of gonads 6.0 (4.8-7.4) 6.9 (4. Li et al. (2008) . c . d Michel et al. (2008) .
Conclusion
The estimates of childhood cancer IRs presented herein are based, for the first time, on high quality national registration data. It is estimated that one out of every 440 children will present with cancer before the age of 15 years. The figures are similar to those for other industrialized countries. The high number of sources per case and histological/cytological confirmations show that the demanding procedures used to actively identify, document and classify the cases were effective. The French National Registries of Childhood Cancer have shown that they are able to (i) fulfil public health missions satisfactorily, including the detailed surveillance of cancer incidence and survival and the evaluation of health care trajectories, (ii) pursue their contributions to the national programme of research on childhood cancer aetiology, and (iii) face new challenges for registration such as the extension of registration to adolescents (15-19 years) and contribute to the long-term follow-up of cases. The constant support from the paediatric oncologists of the French Society against Childhood Cancer is an asset with regard to the long-term success of the programme and maintenance of programme quality.
